PMID- 33348023
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20240226
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 164
DP  - 2021 Feb
TI  - Anlotinib enhances the antitumor activity of radiofrequency ablation on lung 
      squamous cell carcinoma.
PG  - 105392
LID - S1043-6618(20)31700-X [pii]
LID - 10.1016/j.phrs.2020.105392 [doi]
AB  - Anlotinib is a novel molecular targeted drug that has been approved for the 
      treatment of lung adenocarcinoma. Currently these agents are rarely used in the 
      treatment of lung squamous cell carcinoma (LSCC). Bronchoscope-guided 
      radiofrequency ablation (RFA) is a new strategy proposed for the treatment of 
      LSCC that is able to alleviate the obstruction of the respiratory tract caused by 
      LSCC by direct destruction of the tumor tissues. The presence work aims to reveal 
      whether Anlotinib could enhance the antitumor activity of RFA on LSCC cells. The 
      results from real-time PCR (qPCR) confirmed overexpression of targets of 
      anlotinib activity, including receptor tyrosine kinase or the MPAK/PI3K-AKT 
      pathway kinases, in LSCC tissues. Treatment with anlotinib inhibited the 
      survival, in vitro invasion, and migration of LSCC cells. Moreover, the antitumor 
      effects of RFA were investigated using a rodent model of LSCC. The combination of 
      RFA and anlotinib treatment enhanced the antitumor effect of RFA treatment. We 
      propose a combinative strategy of RFA and anlotinib as a novel approach for 
      successful management of LSCC.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Zhou, Wei
AU  - Zhou W
AD  - Department of Respiratory and Critical Care Medicine, Beijing Hospital, National 
      Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of 
      Medical Sciences, Beijing, 100730, PR China. Electronic address: 
      zhouweimsd@163.com.
FAU - Gao, Yongping
AU  - Gao Y
AD  - Department of Respiratory Medicine, Emergency General Hospital, Beijing, 100028, 
      PR China. Electronic address: gaogao_0603@163.com.
FAU - Tong, Yaqi
AU  - Tong Y
AD  - Department of Respiratory and Critical Care Medicine, Beijing Hospital, National 
      Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of 
      Medical Sciences, Beijing, 100730, PR China. Electronic address: 
      yaqitong@126.com.
FAU - Wu, Qingjun
AU  - Wu Q
AD  - Department of Thoracic Surgery, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 
      100730, PR China. Electronic address: wuqingjun3095@bjhmoh.cn.
FAU - Zhou, Yunzhi
AU  - Zhou Y
AD  - Department of Respiratory and Critical Care Medicine, Beijing Hospital, National 
      Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of 
      Medical Sciences, Beijing, 100730, PR China. Electronic address: 
      zhouyunzhi2017@126.com.
FAU - Li, Yanming
AU  - Li Y
AD  - Department of Respiratory and Critical Care Medicine, Beijing Hospital, National 
      Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of 
      Medical Sciences, Beijing, 100730, PR China. Electronic address: 
      liyanming2632@bjhmoh.cn.
LA  - eng
PT  - Journal Article
DEP - 20210107
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - 0 (anlotinib)
RN  - EC 2.7.- (Protein Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Carcinoma, Squamous Cell/genetics/metabolism/*therapy
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Combined Modality Therapy
MH  - Humans
MH  - Indoles/pharmacology/*therapeutic use
MH  - Lung Neoplasms/genetics/metabolism/*therapy
MH  - Mice, Nude
MH  - Protein Kinase Inhibitors/pharmacology/*therapeutic use
MH  - Protein Kinases/genetics/metabolism
MH  - Quinolines/pharmacology/*therapeutic use
MH  - *Radiofrequency Ablation
MH  - Mice
OTO - NOTNLM
OT  - Anlotinib
OT  - Lung squamous cell carcinoma
OT  - Radiofrequency ablation
EDAT- 2020/12/22 06:00
MHDA- 2022/01/06 06:00
CRDT- 2020/12/21 20:11
PHST- 2020/10/26 00:00 [received]
PHST- 2020/12/08 00:00 [revised]
PHST- 2020/12/11 00:00 [accepted]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
PHST- 2020/12/21 20:11 [entrez]
AID - S1043-6618(20)31700-X [pii]
AID - 10.1016/j.phrs.2020.105392 [doi]
PST - ppublish
SO  - Pharmacol Res. 2021 Feb;164:105392. doi: 10.1016/j.phrs.2020.105392. Epub 2021 
      Jan 7.